Analysts Set Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Target Price at $30.57

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) has been given a consensus recommendation of "Buy" by the eight ratings firms that are currently covering the firm, MarketBeat.com reports. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $30.57.

A number of equities research analysts have commented on DAWN shares. The Goldman Sachs Group cut their target price on shares of Day One Biopharmaceuticals from $39.00 to $27.00 and set a "buy" rating for the company in a research report on Tuesday, March 25th. Needham & Company LLC cut their target price on shares of Day One Biopharmaceuticals from $30.00 to $27.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. HC Wainwright reaffirmed a "buy" rating and issued a $36.00 target price on shares of Day One Biopharmaceuticals in a research report on Thursday, April 3rd. Wedbush reaffirmed an "outperform" rating and issued a $25.00 target price on shares of Day One Biopharmaceuticals in a research report on Wednesday, May 7th. Finally, JPMorgan Chase & Co. cut their target price on shares of Day One Biopharmaceuticals from $39.00 to $34.00 and set an "overweight" rating for the company in a research report on Wednesday, March 5th.

Insider Activity

In other news, CEO Jeremy Bender sold 13,964 shares of the business's stock in a transaction on Friday, May 16th. The shares were sold at an average price of $6.26, for a total transaction of $87,414.64. Following the completion of the sale, the chief executive officer now owns 145,737 shares of the company's stock, valued at $912,313.62. The trade was a 8.74% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Charles N. York II sold 4,282 shares of the business's stock in a transaction on Friday, May 16th. The shares were sold at an average price of $6.26, for a total transaction of $26,805.32. Following the sale, the chief financial officer now directly owns 265,231 shares of the company's stock, valued at approximately $1,660,346.06. The trade was a 1.59% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 26,725 shares of company stock valued at $167,299 in the last 90 days. Company insiders own 6.20% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Jane Street Group LLC purchased a new position in shares of Day One Biopharmaceuticals during the 1st quarter valued at $245,000. Optimize Financial Inc lifted its stake in shares of Day One Biopharmaceuticals by 16.0% during the 1st quarter. Optimize Financial Inc now owns 17,960 shares of the company's stock valued at $142,000 after buying an additional 2,473 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of Day One Biopharmaceuticals by 232.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,569,918 shares of the company's stock valued at $12,449,000 after buying an additional 1,097,679 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new position in shares of Day One Biopharmaceuticals during the 1st quarter valued at $384,000. Finally, Parkman Healthcare Partners LLC lifted its stake in shares of Day One Biopharmaceuticals by 4.3% during the 1st quarter. Parkman Healthcare Partners LLC now owns 1,043,162 shares of the company's stock valued at $8,272,000 after buying an additional 42,688 shares in the last quarter. Hedge funds and other institutional investors own 87.95% of the company's stock.

Day One Biopharmaceuticals Price Performance

NASDAQ DAWN traded up $0.03 during mid-day trading on Thursday, reaching $6.30. The stock had a trading volume of 1,123,905 shares, compared to its average volume of 1,116,166. Day One Biopharmaceuticals has a 1 year low of $6.08 and a 1 year high of $16.76. The stock has a market cap of $638.58 million, a PE ratio of -6.12 and a beta of -1.24. The company has a fifty day moving average price of $7.15 and a 200 day moving average price of $10.36.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($0.35) earnings per share for the quarter, topping analysts' consensus estimates of ($0.46) by $0.11. The firm had revenue of $30.76 million during the quarter, compared to analysts' expectations of $30.28 million. As a group, equities research analysts expect that Day One Biopharmaceuticals will post -0.72 earnings per share for the current year.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.